June 28, 2019 06:53 AM EDTUpdated July 3, 07:01 AM
Deals
R&D

Eye­ing a drug launch in ear­ly ’20, Es­pe­ri­on lines up a new, $200M fund­ing deal

John Carroll

Editor & Founder

Es­pe­ri­on CEO Tim Mayleben has fat­tened the biotech’s cash re­serves with an ex­tra $200 mil­lion as he lays the foun­da­tion for the pro­ject­ed com­mer­cial launch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times